Barclays Trims Biogen (NASDAQ:BIIB) Target Price to $200.00
Biogen (NASDAQ:BIIB – Free Report) had its target price trimmed by Barclays from $215.00 to $200.00 in a report published on Thursday morning, Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock. BIIB has been the topic of several other research reports. Wedbush upped their target price on Biogen from […]